These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11743942)

  • 1. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
    Kapur S; Remington G
    Biol Psychiatry; 2001 Dec; 50(11):873-83. PubMed ID: 11743942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.
    Tarazi FI; Zhang K; Baldessarini RJ
    J Pharmacol Exp Ther; 2001 May; 297(2):711-7. PubMed ID: 11303062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atypical antipsychotic drugs].
    Kahn RS
    Ned Tijdschr Geneeskd; 2000 Aug; 144(34):1627-30. PubMed ID: 10972052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
    Oerther S; Ahlenius S
    J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.
    Deveney AM; Waddington JL
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):40-9. PubMed ID: 8935799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.
    Potvin S; Stip E; Roy JY
    Int Clin Psychopharmacol; 2003 May; 18(3):121-32. PubMed ID: 12702890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
    Möller HJ
    Nervenarzt; 2000 May; 71(5):345-53. PubMed ID: 10846709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
    Geddes J; Freemantle N; Harrison P; Bebbington P
    BMJ; 2000 Dec; 321(7273):1371-6. PubMed ID: 11099280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approaches to the management of schizophrenia.
    Lambert TJ; Castle DJ
    Med J Aust; 2003 May; 178(S9):S57-61. PubMed ID: 12720524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
    Kalkman HO; Loetscher E
    Eur J Pharmacol; 2003 Feb; 462(1-3):33-40. PubMed ID: 12591093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atypical antipsychotics].
    Naber D
    Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
    [No Abstract]   [Full Text] [Related]  

  • 19. Bodyweight gain with atypical antipsychotics. A comparative review.
    Wetterling T
    Drug Saf; 2001 Jan; 24(1):59-73. PubMed ID: 11219487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
    Volonté M; Monferini E; Cerutti M; Fodritto F; Borsini F
    J Neurochem; 1997 Jul; 69(1):182-90. PubMed ID: 9202309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.